Pacira BioSciences (PCRX) vs Ultragenyx Pharmaceutical (RARE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Pacira BioSciences (PCRX) has outperformed Ultragenyx Pharmaceutical (RARE) over the past year, gaining 57.5% versus a loss of 51.1%. Over five years, PCRX leads with a -31.7% price change compared with -80.7% for RARE. Ultragenyx Pharmaceutical is the larger company by market cap ($1.53 billion vs $1.45 billion), about 1.1 times the size.
On valuation, Pacira BioSciences trades at a lower forward P/E (10.5x vs 22.9x for Ultragenyx Pharmaceutical). Pacira BioSciences converts more of its revenue into profit, with a net margin of 1.0% versus -85.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PCRX | RARE |
|---|---|---|
| Share price | $36.31 | $15.48 |
| Market cap | $1.45B | $1.53B |
| 1-day change | -0.22% | +1.24% |
| YTD return | +40.30% | -32.70% |
| 1-year return | +57.46% | -51.11% |
| 5-year return | -31.75% | -80.65% |
| P/E ratio (TTM) | 103.74 | — |
| Forward P/E | 10.50 | 22.87 |
| EPS (TTM) | $0.35 | $-5.82 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $726.41M | $673.00M |
| Revenue growth (YoY) | +3.63% | +20.18% |
| Net income (latest FY) | $7.03M | $-575.00M |
| Gross margin | 79.39% | — |
| Operating margin | 2.64% | -79.49% |
| Net margin | 0.97% | -85.44% |
| 52-week high | $36.46 | $39.89 |
| 52-week low | $18.80 | $12.73 |
| Distance from 52-week high | -0.41% | -61.19% |
| Analyst consensus | buy | buy |
| Avg. price target upside | -17.08% | +81.20% |
| Average volume | 1.03M | 3.87M |
| Shares outstanding | 39.91M | 98.59M |
| Employees | 825 | 1,371 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PCRX has outperformed RARE by 108.6 percentage points over the past year.
- Pacira BioSciences is more profitable, keeping 1.0 cents of every revenue dollar as net income versus -85.4 cents for Ultragenyx Pharmaceutical.
- Ultragenyx Pharmaceutical grew revenue faster in its latest fiscal year (+20.18% vs +3.63%).
About Pacira BioSciences
PCRX stock →Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 825 employees
About Ultragenyx Pharmaceutical
RARE stock →Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,371 employees
PCRX vs RARE FAQ
Which is bigger, Pacira BioSciences or Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical (RARE) is larger, with a market capitalization of $1.53B compared with $1.45B for Pacira BioSciences (PCRX).
Which stock has performed better over the past year, PCRX or RARE?
PCRX returned +57.46% over the past 12 months, compared with -51.11% for RARE (price return, excluding dividends). Past performance does not predict future results.
Are Pacira BioSciences and Ultragenyx Pharmaceutical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.